Skip to content
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • Home
  • Contact Us
  • About Us
  • Sitemap
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
  • General
  • Business
  • Education
  • Government
  • Medical
  • Entertainment
  • Sports
  • French
  • Press Releases
    • PR-French
Search
Day: September 3, 2024

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

September 3, 2024

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Music Licensing, Inc. (OTC : SONG) annonce l’acquisition des droits d’auteur de la chanson « Thank God I Got It » de Desiigner, renforçant ainsi son catalogue aussi diversifié que prestigieux

September 3, 2024

NAPLES, État de Floride, 03 sept. 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC : SONG), acteur majeur de l’industrie musicale, se réjouit d’annoncer l’acquisition des

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 3, 2024

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for

Read More
Page1 Page2 Page3
RECENT POSTS

Dr. Rasha Kelej, CEO of Merck Foundation, Leverages Creativity to Combat Infertility Stigma and Support Girl Education

June 30, 2026

Africa CDC Urgently Seeks US$18 Million to Fund Critical Ebola Research

June 30, 2026

Pakistan Airstrikes in Afghanistan Result in Civilian Casualties

June 29, 2026

Africa CDC and WHO Unveil Joint Platform for Ebola Response

June 29, 2026

Thousands of Foreign Nationals Flee South Africa as Anti-Immigrant Protests Intensify

June 29, 2026

Rwandan Foreign Minister Criticizes US Mediation in DR Congo Conflict

June 29, 2026

EU Expresses Deep Concern Over Human Rights Violations in Eastern DRC

June 29, 2026

UN Commission Warns of Grave Human Rights Situation in Eastern Democratic Republic of the Congo

June 29, 2026
Copyright © 2026 Le Congo Tribune. All Rights Reserved.